Traders should monitor upcoming IND filing for CGT1263 and further clinical updates on CGT4255 combinations. Despite recent insider selling of $242.6M, the data readout supports long-term pipeline optionality and could attract partnership interest, especially in the competitive KRAS and HER2+ brain mets spaces.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 17 $37.25entry
- T+1 · 7mo ago −0.67%α −0.48% · $37.00
- T+5 · 7mo ago −1.18%α −1.74% · $36.81
- T+20 · 6mo ago −8.21%α −13.59% · $34.19
- T+60 · 4mo ago +3.38%α −2.76% · $38.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cogent Biosciences presented preclinical data at AACR 2026 for two pipeline candidates: CGT1263, a pan-KRAS(ON) inhibitor with potential differentiation in skin toxicity, and CGT4255, a brain-penetrant ErbB2 inhibitor showing synergy with HER2 ADCs in resistant patients. IND submission for CGT1263 is expected later this year, while Phase 1 trials for CGT4255 are ongoing.
Key Facts
- Presented preclinical data for CGT1263, a pan-KRAS(ON) inhibitor with >500x selectivity for mutant KRAS over HRAS/NRAS, potentially reducing skin toxicity seen with multi-RAS inhibitors.
- CGT1263 shows sustained pERK inhibition and robust antitumor activity in preclinical models, with limited skin suppression suggesting a wider therapeutic window.
- Presented data for CGT4255, a brain-penetrant ErbB2 inhibitor with >100-fold selectivity over EGFR, active against key HER2 mutations and showing synergistic effects when combined with HER2 ADCs like T-DXd.
- IND submission for CGT1263 expected later in 2026; Phase 1 trial for CGT4255 is already ongoing.
- Management highlighted potential for 'multiple blockbuster programs' in the pipeline.
Financial Impact
Preclinical data enhances pipeline value; no immediate revenue impact but increases probability of clinical success and future monetization.
Risk Factors
- Preclinical data may not translate to clinical efficacy in humans.
- High valuation ($5.9B market cap) is sensitive to clinical setbacks or dilution risk.
- Recent insider selling raises concerns about near-term sentiment despite positive data.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276106 |
Track record
13 reports on COGT
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +17.43% at T+20 after the Jun 12, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $31.65 Now $27.44 −13.29% settles Feb 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 5/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- Jun 12, 202622w ago Press Release Bullish 7/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- May 30, 202624w ago Press Release Bullish 8/10 Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
- May 28, 202624w ago Press Release Bullish 8/10 Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers